Mercury Laboratories profit jumps 54% as revenue stays flat
The pharma firm reported a net profit of ₹4.83 crore for FY26, prompting a 35% dividend recommendation for shareholders.
— 1 earlier story on Mercury Laboratories Ltd. →What's new
- Net profit rose 54% to ₹4.83 crore from ₹3.14 crore in the prior year.
- Total revenue was nearly flat at ₹75.94 crore.
- The board recommended a final dividend of 35%, or ₹3.50 per share.
Why this matters
Profitability rose while revenue remained stagnant, indicating the company kept more of its earnings. This is a nano-cap firm with limited liquidity, so the dividend is the primary event for shareholders.
What we're watching
- Details on the 45th Annual General Meeting.
- Whether the company can grow revenue in the next fiscal year.
- Liquidity trends for this ₹94 crore market cap stock.
The full read
Mercury Laboratories reported a 54% jump in net profit for the fiscal year ended March 31, 2026, reaching ₹4.83 crore against ₹3.14 crore in the previous year. Revenue was nearly flat at ₹75.94 crore. The board recommended a final dividend of 35%, or ₹3.50 per share. The filing also confirmed the re-appointment of internal and cost auditors and provided notice for the upcoming 45th Annual General Meeting. As a nano-cap entity with a market valuation of roughly ₹94 crore, these results are a standard annual disclosure. The primary development is that the company increased its profit despite the lack of revenue growth. Investors should view this as a routine update.
Questions answered
- How did Mercury Laboratories perform in FY26?
- The company saw its net profit rise by 54% to ₹4.83 crore, compared to ₹3.14 crore in the previous year. Revenue remained mostly stable at ₹75.94 crore.
- What is the dividend payout for shareholders?
- The board recommended a final dividend of 35%, which equates to ₹3.50 per share.
- Are there any changes to the company's auditors?
- No. The filing confirms the re-appointment of internal and cost auditors.
- What is the scale of Mercury Laboratories?
- It is a nano-cap pharmaceutical firm with a market capitalization of approximately ₹94 crore.
Story so far
All notes on MERCURYLAB →- 29 May 2026 · 4:22 PM IST Mercury Laboratories profit jumps 54% as revenue stays flat
- 1d ago Mercury Laboratories lifts annual profit by 59% to ₹4.93 crore